Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity

Treatment of advanced head and neck squamous cell carcinoma (HNSCC) is plagued by low survival and high recurrence rates, despite multimodal therapies. Presently, cisplatin or cetuximab is used in combination with radiotherapy which has resulted in minor survival benefits but increased severe toxici...

Descripción completa

Detalles Bibliográficos
Autores principales: Dohmen, Amy J.C., Qiao, Xiaohang, Duursma, Anja, Wijdeven, Ruud H., Lieftink, Cor, Hageman, Floor, Morris, Ben, Halonen, Pasi, Vens, Conchita, van den Brekel, Michiel W.M., Ovaa, Huib, Neefjes, Jacques, Zuur, Charlotte L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650312/
https://www.ncbi.nlm.nih.gov/pubmed/29088757
http://dx.doi.org/10.18632/oncotarget.18034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650312/
https://www.ncbi.nlm.nih.gov/pubmed/29088757
http://dx.doi.org/10.18632/oncotarget.18034

Ejemplares similares